Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AUSTRAL Trial: An Open-Label, Multicenter, Phase II Study Of Radiotherapy Followed By Durvalumab (MEDI4736) And Ceralasertib (AZD6738) In Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

NCT06680050 is registered in ClinicalTrials.gov with Mario Negri Institute for Pharmacological Research as lead sponsor.

NCT NCT06680050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06680050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AUSTRAL Trial: An Open-Label, Multicenter, Phase II Study Of Radiotherapy Followed By Durvalumab (MEDI4736) And Ceralasertib (AZD6738) In Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Lead sponsor
Mario Negri Institute for Pharmacological Research
Phase
Phase 2
Overall status
Recruiting
Start date
August 7, 2025
Completion date
January 31, 2029
Enrollment
21 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer nsclc